MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

125.60
-1.15
-0.91%
After Hours: 121.83 -3.77 -3.00% 16:03 05/26 EDT
OPEN
127.19
PREV CLOSE
126.75
HIGH
129.06
LOW
125.02
VOLUME
330.29K
TURNOVER
0
52 WEEK HIGH
212.00
52 WEEK LOW
117.58
MARKET CAP
15.17B
P/E (TTM)
-16.7914
1D
5D
1M
3M
1Y
5Y
Mass. life sciences leaders urge action on 'epidemic' of gun violence
In wake of Tuesday's mass shooting at an elementary school in Uvalde, Texas, Massachusetts life sciences leaders are urging the industry to come together to limit access to guns.
American City Business Journals · 1d ago
Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease
Benzinga · 2d ago
Alnylam kidney disorder therapy Oxlumo improves cardiac measures in new data from phase 3 trial
Alnylam Pharmaceuticals (NASDAQ:ALNY) said new analysis from a late-stage study of its drug Oxlumo (lumasiran) showed that the drug helped improve cardiac measures, calcium deposit levels and kidney stone events in
Seekingalpha · 2d ago
BRIEF-Alnylam Presents New Results From Illuminate-C Phase 3 Study Of Lumasiran In Patients With Advanced Primary Hyperoxaluria Type 1
reuters.com · 2d ago
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
CAMBRIDGE, Mass., May 24, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from the six-month primary analysis period of the ILLUMINATE-C Phase 3 open-label study of lumasiran, ...
Business Wire · 2d ago
Alnylam Pharmaceuticals' Phase 3 Study Shows Improvement in Exploratory Endpoints in Patients With Rare Genetic Disease PH1
MT Newswires · 2d ago
Alnylam Presents New 18-Month Results From Exploratory Cardiac Endpoints In HELIOS-A Phase 3 Study Of Investigational Vutrisiran
–New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement
Benzinga · 3d ago
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
CAMBRIDGE, Mass., May 23, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran...
Business Wire · 3d ago
More
No Data
Learn about the latest financial forecast of ALNY. Analyze the recent business situations of Alnylam Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

27.27%Strong Buy
45.45%Buy
22.73%Hold
4.55%Under-perform
0.00%Sell
Analyst Price Target
The average ALNY stock price target is 207.85 with a high estimate of 430.00 and a low estimate of 96.00.
High430.00
Average207.85
Low96.00
Current 125.60
EPS
Actual
Estimate
-1.73-1.30-0.86-0.43
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 590
Institutional Holdings: 123.82M
% Owned: 102.49%
Shares Outstanding: 120.81M
TypeInstitutionsShares
Increased
145
8.87M
New
64
1.48M
Decreased
143
6.33M
Sold Out
55
2.09M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Chairman/Executive Director
Michael Bonney
President
Akshay Vaishnaw
Chief Executive Officer/Director
Yvonne Greenstreet
Chief Financial Officer/Executive Vice President
Jeffrey Poulton
Executive Vice President/Secretary
Indrani Franchini
Executive Vice President
Pushkal Garg
Other
Tolga Tanguler
Lead Director/Independent Director
Amy Schulman
Independent Director
Dennis Ausiello
Independent Director
Olivier Brandicourt
Independent Director
Marsha Fanucci
Independent Director
Margaret Hamburg
Independent Director
David Pyott
Independent Director
Colleen Reitan
Independent Director
Phillip Sharp
No Data
No Data
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics are focused in four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and central nervous system/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. The GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. The OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. The Leqvio is used for the treatment of adults with hypercholesterolemia.

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.